経営成績
- 売上高: 450.39億円 (3.5%増)
- 営業利益: 22.63億円 (24.6%減)
- 経常利益: 25.92億円 (23.9%減)
- 親会社株主に帰属する当期純利益: 10.41億円 (29.6%減)
ライフサイエンス業界の研究開発費の縮減と市場回復の遅れが影響。試薬、機器、受託、遺伝子医療の全カテゴリで増収も、検査関連試薬の減収と売上構成変化が減益の要因。
財政状態
- 総資産: 1253.34...
Continue reading
The following content is a summary generated by the generative AI "Gemini" based on PDFs of timely disclosures published by companies.
The accuracy of the summary content cannot be guaranteed. Please be sure to check the original timely disclosure PDF before making any investment decisions.